Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2 + Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy.

Background & Aims: Because pancreatic cancer responds poorly to chemotherapy and immunotherapy, it is necessary to identify novel targets and compounds to overcome resistance to treatment.
Methods: This study analyzed genomic single nucleotide polymorphism sequencing, single-cell RNA sequencing, and spatial transcriptomics. Ehf-knockout mice, KPC (LSL-Kras ^G12D/+ , LSL-Trp53 ^R172H/+ and Pdx1-Cre) mice, CD45.1 ⁺ BALB/C nude mice, and CD34 ⁺ humanized mice were also used as subjects. Multiplexed immunohistochemistry and flow cytometry were performed to investigate the proportion of tumor-infiltrated C-X-C motif chemokine receptor 2 (CXCR2) ⁺ neutrophils. In addition, multiplexed cytokines assays and chromatin immunoprecipitation assays were used to examine the mechanism.
Results: The TP53 mutation-mediated loss of tumoral EHF increased the recruitment of CXCR2 ⁺ neutrophils, modulated their spatial distribution, and further induced chemo- and immunotherapy resistance in clinical cohorts and preclinical syngeneic mice models. Mechanistically, EHF deficiency induced C-X-C motif chemokine ligand 1 (CXCL1) transcription to enhance in vitro and in vivo CXCR2 ⁺ neutrophils migration. Moreover, CXCL1 or CXCR2 blockade completely abolished the effect, indicating that EHF regulated CXCR2 ⁺ neutrophils migration in a CXCL1-CXCR2-dependent manner. The depletion of CXCR2 ⁺ neutrophils also blocked the in vivo effects of EHF deficiency on chemotherapy and immunotherapy resistance. The single-cell RNA-sequencing results of PDAC treated with Nifurtimox highlighted the therapeutic significance of Nifurtimox by elevating the expression of tumoral EHF and decreasing the weightage of CXCL1-CXCR2 pathway within the microenvironment. Importantly, by simultaneously inhibiting the JAK1/STAT1 pathway, it could significantly suppress the recruitment and function of CXCR2 ⁺ neutrophils, further sensitizing PDAC to chemotherapy and immunotherapies.
Conclusions: The study demonstrated the role of EHF in the recruitment of CXCR2 ⁺ neutrophils and the promising role of Nifurtimox in sensitizing pancreatic cancer to chemotherapy and immunotherapy.
(Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)